2024, Vol. 6, Issue 1, Part C

Methods: This review synthesizes current literature on venoarterial (VA) ECMO, focusing on its implementation in emergency settings for patients experiencing CS. We analyzed clinical studies and registry data to evaluate the efficacy, indications, and contraindications of VA ECMO, while also assessing hemodynamic outcomes and patient selection criteria.

Results: VA-ECMO provides immediate circulatory and respiratory support, facilitating organ recovery in patients unresponsive to conventional treatments. It is particularly beneficial in cases of acute myocardial infarction and fulminant myocarditis. However, the selection of suitable candidates is critical, as poor prognosis in certain patients limits the benefits of ECMO. Complications such as infection, bleeding, and device-related issues pose significant risks. Recent data from the Extracorporeal Life Support Organization (ELSO) registry indicate a marked increase in VA-ECMO utilization, with survival rates showing improvement, underscoring the need for standardized protocols.

Conclusion: VA-ECMO represents a vital therapeutic option for managing cardiogenic shock in emergency settings, offering a bridge to recovery or further interventions. However, careful patient selection and ongoing monitoring are essential to optimize outcomes and minimize complications. Future research should prioritize randomized controlled trials to establish evidence-based guidelines for ECMO use in cardiogenic shock.